GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
Issued: London, UK
For media and investors only
Download
(PDF, 175.4KB)
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through 3 full seasons, including in people at increased risk
Safety and reactogenicity...
Zur Pressemeldung auf www.gsk.com